{"disease":{"id":"tumor-infiltrating-lymphocyte","name":"tumor infiltrating lymphocyte"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05250336","title":"Tumor-Infiltrating Lymphocytes and Programmed Cell Death - Ligand 1 in Breast Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","has_results":false},{"nct_id":"NCT05270824","title":"Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT05152797","title":"Efficacy and Safety of TILs in Treatment of Patients With Advanced or Metastatic Refractory Gynecological Cancer","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":91,"lead_sponsor_name":"Women's Hospital School Of Medicine Zhejiang University","has_results":false},{"nct_id":"NCT05087745","title":"A Clinical Study on TIL for the Treatment of Advanced Solid Tumors","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Shanghai Juncell Therapeutics","has_results":false},{"nct_id":"NCT05098197","title":"A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Shanghai Juncell Therapeutics","has_results":false},{"nct_id":"NCT05098184","title":"A Study of GC101 TIL in Advanced Melanoma (10hospital)","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Shanghai Juncell Therapeutics","has_results":false},{"nct_id":"NCT05417750","title":"A Phase I Study of GC101 TIL in Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Shanghai Juncell Therapeutics","has_results":false},{"nct_id":"NCT06488950","title":"A Study of TIL in Advanced Solid Tumors (DFGD)","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Shanghai Juncell Therapeutics","has_results":false},{"nct_id":"NCT06120712","title":"A Study of GC101 TIL in Advanced Melanoma (BZ)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Shanghai Juncell Therapeutics","has_results":false},{"nct_id":"NCT06828328","title":"A Study of GC203 TIL in PDCA (RJ)","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Shanghai Juncell Therapeutics","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}